Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer

Does the combination of ERBB2-biparatopic antibody (anbenitamab) and albumin-bound docetaxel (HB1801) increase the total pathological complete response (tpCR) rate compared with the standard regimen of trastuzumab, pertuzumab, and docetaxel in patients with ERBB2-positive breast cancer? In this randomized clinical trial that included 521 patients with early or locally advanced ERBB2-positive breast cancer, the tpCR rate was significantly higher in the anbenitamab and HB1801 group compared with the control group; both regimens had manageable safety profiles. These findings suggest that neoadjuvant anbenitamab and HB1801 led to clinically meaningful tpCR improvement; this new combination might establish a new standard for neoadjuvant treatment in ERBB2-positive breast cancer.

Corresponding Authors: Zhi-Ming Shao, MD, (zhimin_shao@yeah.net), and Lei Fan, MD, (teddyfl@163.com), Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dong-An Rd, Shanghai, 200032, China

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.